The potential of clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9)based therapeutic genome editing is hampered by difficulties in the control of the in vivo activity of CRISPR-Cas9. To minimize any genotoxicity, precise activation of CRISPR-Cas9 in the target tissue is desirable. Here, we show that, by complexing magnetic nanoparticles with recombinant baculoviral vectors (MNP-BVs), CRISPR-Cas9-mediated genome editing can be activated locally in vivo via a magnetic field. The baculoviral vector was chosen for in vivo gene delivery because of its large loading capacity and ability to locally overcome systemic inactivation by the complement system. We demonstrate that a locally applied magnetic field can enhance the cellular entry of MNP-BVs, thereby avoiding baculoviral vector inactivation and causing a transient transgene expression in the target tissue. Because baculoviral vectors are inactivated elsewhere, gene delivery and in vivo genome editing via MNP-BVs are tissue specific.
T he clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) system is a revolutionary genome editing technology that can efficiently modify target genes in mammalian cells 1 . Preclinical studies have shown that the CRISPR-Cas9 system provides unprecedented opportunities for treating a variety of genetic and infectious diseases [2] [3] [4] [5] [6] [7] . Although in vitro genome editing of cultured cells has many clinical applications, to potentially cure a wide range of diseases, including muscular dystrophy, cystic fibrosis and cancer 8, 9 , it is necessary to perform in vivo genome editing. The CRISPR-Cas9 system targets a short stretch of DNA via the hybridization of a complementary guide RNA and binding of the Cas9 protein, which recognizes a protospacer adjacent motif 1 . The guide RNAs can hybridize to DNA sequences containing base mismatches and DNA and RNA bulges compared with the intended target sequence 10 . Consequently, the CRISPR-Cas9 system can have off-target activities, causing gene mutations, deletions, insertions or translocations, which may lead to tumorigenic or other deleterious events [10] [11] [12] [13] . A major challenge for clinical applications of CRISPR-Cas9-based in vivo genome editing is, therefore, to selectively activate the CRISPR-Cas9 system in the desired tissue or organ to maximize the therapeutic efficacy and minimize genotoxicity.
To improve the specificity of the CRISPR-Cas9 system, many tools have been developed for identifying potential guide RNA off-target sites 14 , and the Cas9 nucleases have been designed with controllable nuclease activities 15, 16 . For example, the Cas9 nucleases have been fragmented into non-functional units, which can dimerize to form active nucleases under blue light radiation 16 . Cas9 can also be delivered as inducible transgenes that can only be translated in the presence of a chemical cue; for example, doxycycline 15 . However, in in vivo applications, optical signals cannot penetrate deeply into the body owing to the strong absorption and scattering of light by biological tissues. Chemically regulated Cas9 expression relies on the biodistribution of transgenes. Alternatively, in vivo genome editing can be controlled through targeted delivery of the CRISPR-Cas9 system. In particular, the viral vectors with tissue tropism (for example, the adeno-associated viral vector 17 ) are being explored for tissue-specific genome editing in vivo 3, 13, 18 . However, most viral vectors for in vivo gene delivery are derived from the viruses originated from human or other mammals 4 . It is difficult to control the systemic dissemination and replication of these viral vectors, which increases the risk of genotoxicity 19 .
Recent studies have shown that magnetic nanomaterials can be used to alter molecular or cellular processes in vivo mechanically or thermally in response to a magnetic field [20] [21] [22] [23] . Compared with chemical or optical signals, a magnetic field with a strength of 1.5-3.0 Tesla, such as that in a typical magnetic resonance imaging scanner, has no evident adverse effect to the human body and the magnetic field is not attenuated by the tissue 24 . Here, we show the development of a magnetic responsive gene delivery system consisting of a baculoviral vector complexed with magnetic iron oxide nanoparticles (MNP-BV) that enables spatial control of in vivo genome editing.
The baculoviral vector is derived from a cylindrical insect virus (Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV); 30~60 nm in diameter and 250~300 nm in length) 25 . The large size of the baculoviral vector allows an extraordinary DNA packing capacity (> 38 kilobases) compared with most other viruses, thus enabling the integration of multiple gene expression cassettes into a single viral vector 26 . Although the baculoviral vector lacks the ability to replicate in mammalian cells, it can transduce many types of mammalian cells with high efficiency and low cytotoxicity, providing robust and transient gene expression [25] [26] [27] [28] [29] . However, in vivo applications of baculoviral vector have been hurdled by its inactivation by the complement system 27 . Previous studies have shown that baculoviral vector injected systemically can trigger the classical pathway of the complement system and lead to a significant reduction of viral transduction 30 . Baculoviral vector injected locally into muscle or tumour can induce moderate transduction due to reduced exposure to the complement system 31, 32 . It has been shown that baculoviral vectors can transduce tissues that are naturally immune privileged, such as the brain, eye or testis 33, 34 . The complement-induced baculoviral vector inactivation can also be circumvented to some extent by protecting the baculoviral vector with a surface coating or treating the animal with agents that inhibit the complement system 30, 35, 36 . In this study, we show that serum inactivation of baculoviral vector can be used as an 'off ' switch to limit systemic activities of the baculoviral vector, and an external magnetic field can serve as an 'on' switch for tissue-specific genome editing by promoting margination and cell entry of the MNP-BV complex locally. This hybrid nanoparticle-viral vector system provides a unique delivery vehicle for spatial control of CRISPR-Cas9mediated in vivo genome editing.
Results and discussion
Construction of the MNP-BV vector. Recombinant baculoviral vector was produced, purified and concentrated according to published protocols (see Methods). The titre of various baculoviral vectors was determined by a quantitative PCR (qPCR) assay and plaque assay ( Supplementary Fig. 1 ). Magnetic iron oxide nanoparticles (MNPs) that can bind to baculoviral vectors were synthesized in three steps. First, magnetite nanocrystals were synthesized through thermodecomposition of iron acetylacetonate in benzyl ether 37 . As-synthesized nanocrystals were 15.5 ± 1.1 nm in diameter and had a saturation magnetization of 87.2 emu g −1 , similar to that of bulk magnetite ( Supplementary Fig. 2a,b ). Water-dispersible MNPs were generated by coating the nanocrystals with copolymers of phospholipid and polyethylene glycol (PEG) using a dual solvent exchange method 38 . Coated MNPs (MNP-PEG) were then conjugated with TAT peptide (GRKKRRQRRRPQ) 39 -a positively charged peptide used to facilitate the interaction between MNPs and baculoviral vector surfaces. TAT peptide conjugation to MNPs was confirmed by zeta potential measurements, gel shifting assay and DNA retardation assay ( Supplementary Table 1 and Supplementary Fig. 2c,d ). TAT-conjugated MNPs (MNP-TAT) can disperse in aqueous buffers with negligible magnetic interactions, but on exposure to a magnetic field, they migrate against the field gradient as nanomagnets. In most of the experiments reported in this study, the magnetic field was generated using NdFeB block magnets with a residual induction of 1.48 Tesla ( Supplementary Fig. 3 ).
When MNP-TAT was mixed with baculoviral vector in phosphate buffered saline (PBS), multiple MNP-TATs could attach to a single baculoviral vector to form the MNP-BV hybrid ( Fig. 1a ). We found that, when mixed with MNP-TAT, more than 90% of baculoviral vectors could be pulled down by a magnetic plate, while mixing with MNP-PEG (that is, without TAT) had a negligible effect on the dispersion of baculoviral vectors ( Fig. 1b ). When MNP-TAT was pre-incubated with heparin-a negatively charged moleculethe pulldown efficiency was reduced to 60% ( Fig. 1b ). Further pulldown assays were performed, respectively, using MNPs conjugated with positively charged peptide polyarginine (MNP-polyArg) instead of TAT, and mixed with adenoviruses instead of baculoviral vector, revealing similar trends ( Fig. 1b ). Our results suggest that the interaction between baculoviral vector and MNP-TAT is largely due to the non-specific electrostatic interactions between the positively charged peptide and negatively charged viral surface 40 . Importantly, when serum was added to the sample, the pulldown efficiency of baculoviral vector mixed with MNP-TAT was only reduced by 10% ( Fig. 1b ), suggesting that baculoviral vector and MNP-TAT could remain associated during systemic circulation.
Nanomagnets improve cell entry and transduction efficiency of baculoviral vector in vitro.
We further investigated the effect of nanomagnets on the interactions of baculoviral vector with cultured hepatoma cells (Hepa 1-6 cells) that have high baculoviral vector infectability ( Supplementary Fig. 4 ) 41 . The cells were incubated with baculoviral vector or MNP-BV for 10 min-a much shorter time than is used in a typical in vitro viral transduction assay. Cells incubated with baculoviral vector alone had negligible intracellular baculoviral vector, as examined by immunostaining with the anti-vp39 antibody ( Fig. 1c) [41] [42] [43] . In contrast, under a magnetic field, a large number of MNP-BV complexes entered the cells after a short period (10 min) of incubation ( Fig. 1c and Supplementary Videos 1 and 2). Transmission electron microscopy (TEM) images of cell crosssections show co-existence of MNPs and baculoviral vector in the lysosomes ( Supplementary Fig. 5 ), suggesting concurrent cellular internalization of MNPs and baculoviral vector.
To examine the effect of nanomagnets on baculoviral vectorinduced transgene expression in vitro, we constructed BV-LUC and BV-eGFP, baculoviral vectors containing the luciferase and enhanced green fluorescent protein (eGFP) cassette, respectively ( Fig. 2a ). BV-eGFP was mixed with MNP-TAT, and the mixture was incubated with Hepa 1-6 cells under a magnetic field for 30 min, resulting in a much larger number of eGFP-positive cells compared with BV-eGFP alone, BV-eGFP under a magnetic field but without MNPs, or BV-eGFP with MNPs but without an applied magnetic field ( Fig. 2b,d ). When BV-eGFP was mixed with MNPs labelled with the fluorophore DiI (maximum excitation/emission wavelengths = 549/565 nm), MNPs could be observed in perinuclear vesicles in the cells that had strong eGFP expression, indicating that transgene expression occurred in the presence of MNPs (Fig. 2c ). The baculoviral vector transduction efficiency was determined by quantifying eGFP fluorescence and luciferase activity in the cells incubated with BV-eGFP and BV-LUC, respectively ( Fig. 2d,e ). The luciferase activity shown in Fig. 2e was normalized against that in cells incubated with BV-LUC alone for 4 h, resulting in a high level of luminescence ( Supplementary Fig. 4c ).
Clearly, having baculoviral vector mixed with MNPs or under the magnetic field alone did not affect the transgene expression ( Fig. 2d,e ). Having baculoviral vector mixed with MNPs and applying a magnetic field could increase the transgene expression fivefold compared with that of baculoviral vector alone ( Fig. 2e ). We found that with both MNPs and an applied magnetic field, BV-eGFP and BV-LUC could efficiently transduce many other cell types, such as HeLa, U87 and human umbilical vein endothelial cells (HUVECs) ( Supplementary Fig. 6 ). The increase in the transgene expression due to nanomagnets is larger in cells with lower baculoviral vector infectability, such as HeLa cells ( Supplementary Fig. 7 ). At the multiplicity of infection (MOI) used in the in vitro experiments, MNP-BV had a low effect on cell viability, similar to a lipofectaminebased transfection ( Supplementary Fig. 8 ) 26 . However, MNP-BV could have moderate toxicity if a large amount of MNP is used with high baculoviral vector MOI. The results shown in Fig. 2 were obtained with an MNP-tobaculoviral vector ratio of ~10 4 :1 in the MNP-BV mixture, so the vast majority of MNPs were not attached to baculoviral vector. Using MNPs without conjugated TAT peptide, we found that nanomagnets alone could enhance the cellular uptake of baculoviral vector as well as BV-LUC-induced transgene expression ( Supplementary Fig. 9 ). It has been shown that an important pathway of cellular uptake of baculoviral vector is the macropinocytosis mediated by the baculovirus envelope glycoprotein gp64, which depends on actin polymerization in the cells 44 . Consistently, we found that the cells treated with cytochalasin D-an actin depolymerization agent-showed disrupted actin filament structure and reduced baculoviral vector uptake compared with control (untreated) cells ( Supplementary Fig. 9 ). However, subsequent use of MNPs together with the magnetic field could partially restore actin filament formation and baculoviral vector uptake. Our results suggest that the increase in the cellular uptake of MNP-BV complexes is partly attributable to magnetic force-induced changes in actin filaments 21, 45 .
Nanomagnets can help overcome serum inactivation of baculoviral vector in vitro.
To determine whether MNPs can protect baculoviral vector from serum inactivation similar to that of polymer coating or ligand displaying 25, 27, 28 , we performed baculoviral vector transduction in a culture medium with 50% adult mouse serum (AMS), which contains the complement system to inactivate baculoviral vector. When the cells were incubated with baculoviral vector alone, baculoviral vector transduction was suppressed by AMS, as indicated by the low percentage of eGFP-positive cells and negligible luciferase expression ( Fig. 3a,b ). Neither MNPs nor the magnetic field alone could rescue BV-eGFP or BV-LUC transduction. In contrast, when associated with MNPs and under an applied magnetic field, BV-eGFP had high transduction efficiency and BV-LUC induced a high level of luciferase expression in Hepa 1-6 cells ( Fig. 3a,b ), suggesting that the inactivation of baculoviral vector by AMS was diminished. When MNP-BV-LUC was used under a magnetic field, the level of transgene expression in the presence of AMS was even higher than that induced by BV-LUC alone without AMS (Figs. 2e and 3b).
To further elucidate the mechanisms underlying the complement evasion, we quantified the baculoviral vector genome copy and transgene expression in baculoviral vector-transduced cells ( Fig. 3c ). AMS dramatically decreased the endocytosis of baculoviral vector, as indicated by the much-reduced baculoviral vector genome copies in cultured cells. MNP-TAT alone did not have a significant effect on the baculoviral vector endocytosis, nor the transgene expression. Under an applied magnetic field, the endocytosis of baculoviral vector complexed with MNP-TAT increased 20-fold in the normal medium and more than fourfold in the presence of AMS. These results suggest that baculoviral vector inactivation was mainly due to inhibition of baculoviral vector cell entry by either enzymatic degradation of baculoviral vector or masking of the baculoviral vector surface. It is likely that with MNP-BVs the physical forces generated by MNPs under the magnetic field induce a rapid cellular uptake of baculoviral vector, which may outpace the cascade involved in serum-medicated baculoviral vector inactivation. Even when the MNP-BVs were mixed with AMS for 30 min before applying the magnetic field, the level of baculoviral vector internalization was not reduced, confirming the high stability of the MNP-BV complex in the serum found in our pulldown study ( Fig. 1b ). However, having MNPs complexed with baculoviral vector reduced the levels of luciferase messenger RNA (mRNA) in Hepa 1-6 cells, possibly due to interference with the endosomal escape of baculoviral vector. The combined effects of MNPs and the magnetic field on overcoming the baculoviral vector evasion from the complement system are depicted schematically in Supplementary Fig. 10 . Our results suggest that MNPs together with a magnetic field can enhance the endocytosis of baculoviral vector through enrichment of baculoviral vectors on the cell surface, and the increase in the interaction of baculoviral vector with cell membrane via positively charged TAT peptide. It is also possible that magnetic force exerted on MNPs on the cell surface and in the intracellular vesicles may induce changes in actin filaments, similar to what we reported previously 23, 46 , which may further increase baculoviral vector endocytosis. However, this does not rule out other mechanisms, such as endocytosis mediated by microtubules and heparin sulfate.
We investigated whether serum inactivation and magnetic activation could be combined to provide spatial control of baculoviral vector transduction. Cells seeded in a chamber slide were incubated with MNP-BV-eGFP in the presence of AMS, and only half of the chamber was placed on a block magnet. We found that at 12 h posttransduction, most eGFP-positive cells were in the area above the magnet (Fig. 3d ). The level of transgene expression increased with the MNP-to-baculoviral vector ratio and the strength and duration of the applied magnetic field ( Supplementary Fig. 11 ). When a mixture of baculoviral vector and MNP-TAT was infused through silicone tubing at physiologically relevant flow rates, baculoviral vector could be captured by a block magnet placed next to the tubing ( Supplementary  Fig. 12 ). This suggests that block magnets can increase the margination of the MNP-BV complex circulating in the blood vessels and enhance the contact between MNP-BV and the vascular endothelium. In addition, an artificial vein was created by growing a layer of endothelial cells in the silicone tubing. The MNP-BV-eGFP vector in culture medium containing AMS was infused into the tubing at a flow rate of 7 mm s −1 . A section of the tubing was placed along a block magnet during the infusion. After overnight incubation, we found that only the cells in the tubing next to the magnet showed eGFP fluorescence ( Fig. 3e ), further demonstrating the ability to provide spatial control of baculoviral vector transduction.
We integrated the cassettes encoding eGFP, Streptococcus pyogenes Cas9 and guide RNA targeting the mouse Vegfr2 gene into one plasmid for baculoviral vector packaging (BV-CRISPR), thanks to the baculoviral vector's large DNA loading capacity (> 38 kilobases) ( Fig. 4a ). When delivered as a plasmid or via the BV-CRISPR vector, respectively, into Hepa 1-6 cells, the CRISPR-Cas9 system had cutting efficiencies of 9-30% of the mouse Vegfr2 gene ( Supplementary Fig. 13 ). When Hepa 1-6 cells were incubated with the MNP-BV vector carrying CRISPR-Cas9 (MNP-BV-CRISPR) in the medium containing 50% AMS, both the eGFP expression and CRISPR-Cas9-induced gene modification rate increased with the strength of the applied magnetic field (Fig. 4b ). Without applying a magnetic field to overcome baculoviral vector inactivation by AMS, there was no eGFP expression or site-specific Vegfr2 gene modification in Hepa 1-6 cells (Fig. 4b ).
In vivo baculoviral vector transduction and genome editing via local injection. It has been shown that conventional viral vectors (such as adenoviral vectors) injected into tumour tissue locally (intratumoral injection) can disseminate through the systemic circulation and induce a high level of transgene expression in the liver 19 . In contrast, in vivo transduction of baculoviral vector via local injection is most effective in immune privileged tissues lacking the complement system 33, 34 ; otherwise, baculoviral vector transduction is suppressed, presumably caused by partial exposure to the complement system due to local bleeding and in situ secretion of the complement factors. We performed intratumoral injection of baculoviral vector and found that BV-LUC could induce moderate transgene expression in subcutaneous tumours (Fig. 5a,b ). If the tumour was injected with MNP-BV-LUC and subjected to a magnetic field for 1 h post-injection, the transgene expression was increased markedly ( Fig. 5a,b ). Ex vivo imaging of dissected tumours and vital organs showed that the transgene expression was limited to injected tumour tissue ( Fig. 5c,d ). Local baculoviral vector transduction and transgene expression could also be achieved in the mouse hind limb following intramuscular injection ( Supplementary Fig. 14) .
To examine MNP-BV-CRISPR-induced genome editing, we injected the mice intratumorally with MNP-BV-CRISPR and placed the tumour under a magnetic field. Following the workflow illustrated in Fig. 5e , at 24 h post-MNP-BV-CRISPR delivery, the eGFP-positive cells were harvested from the mouse tumours and T7E1 assays were performed to quantify the gene modification rate. We found that MNP-BV-CRISPR induced site-specific gene modification in transduced cells with a ~30% indel rate (Fig. 5f ).
In a parallel study, at 96 h post-transduction, the mouse tumours and vital organs were homogenized and the modifications in the mouse Vegfr2 gene were analysed by next-generation sequencing (NGS). We found that gene modification was only detectable in the tumour (Fig. 5g ). The indel rates (0 to 4.7%) varied among the samples collected from different parts of the tumour as a result of the heterogeneous distribution of the magnetic field and MNP-BV-CRISPR following direction injection. A representative mutation pattern detected by NGS of the mouse Vegfr2 locus is summarized in Supplementary Fig. 15 . Therefore, local injection of MNP-BV coupled with a magnetic field provides a means for efficient local gene delivery and tissue-specific genome editing, overcoming the challenge of non-specific dissemination.
In vivo activation of baculoviral vector transduction and local genome editing via systemic delivery. It is well known that viral vectors delivered via systemic injection can reach the vascular endothelium and-in the case of fenestrated or leaky vessels-the stromal and parenchymal cells behind the vessel wall. Although baculoviral vector administrated intravenously can circulate throughout the body, circulating baculoviral vector can trigger the classical complement cascade that leads to baculoviral vector inactivation 30 . As shown in our in vitro baculoviral vector transduction study, a magnetic field can drive MNP-BV towards the cell surface and enhance its cellular uptake with faster kinetics, which overcomes baculoviral vector inactivation by the complement system. We expect that magnetic activation of baculoviral vector can enable selective in vivo genome editing in the tissue exposed to the applied magnetic field. First, we tested the nanomagnet-based approach in vivo with the mouse liver, which can be readily influenced by a block magnet. MNP-BV-LUC was administrated systemically through tail vein injection, and the mouse liver was positioned on top of a block magnet for 1 h (Fig. 6a ). Transgene expression was evaluated by examining the luciferase activity with live animal imaging. Consistent with the results from our in vitro studies, the mice treated with MNP-BV-LUC and subjected to a magnetic field showed strong luminescence in the liver, whereas there was no luminescence in the mice treated with BV-LUC alone, or with MNP-BV-LUC but without applying a magnetic field (Fig. 6b,c) . Ex vivo examination confirmed that the high luciferase expression was only in the liver tissue exposed to the magnetic field; other vital organs, including the heart, lung, spleen and kidney, did not show a luminescence signal ( Fig. 6d,e ). The level of luciferase expression in the liver also increased with the strength of the magnetic field ( Supplementary Fig. 16 ). Importantly, the luciferase expression in the mouse liver lasted less than 48 h ( Fig. 6f,g) , indicating that nanomagnet-induced transgene expression is transient. MNP-BV-LUC did not induce significant acute liver damage ( Supplementary Figs. 17 and 18) .
The MNP-BV transduction activated by a magnetic field was further examined in the spleen, where a small block magnet was placed next to the spleen following the tail vein injection of MNP-BV ( Supplementary Fig. 19a ). At 24 h post-transduction, ex vivo imaging of dissected organs showed that the luciferase activity in the spleen was significantly higher than in the heart, lung and kidney ( Supplementary Fig. 19b,c) , suggesting that the nanomagnetinduced transgene expression in vivo can be switched on locally with good tissue specificity. Since the liver was exposed to the applied magnetic field as well, luciferase activity also increased in the liver.
For in vivo genome editing, the mice were injected with MNP-BV-CRISPR and subjected to a magnetic field targeting the mouse liver similar to that shown in Fig. 6a . Following the workflow illustrated in Fig. 5e , at 24 h post-MNP-BV-CRISPR delivery, the eGFPpositive cells were harvested from the mouse liver tissue and T7E1 assays were performed to quantify the gene modification rate. We found that the nanomagnets induced site-specific gene modification in the transduced mouse liver cells with a ~50% indel rate (Fig. 6h) . A representative pattern of the indels at the Vegfr2 target locus is shown in Supplementary Fig. 20 . Our NGS analysis suggests that ~96% of mutations may lead to a frameshift (3N + 1, 3N + 2) . In a parallel experiment, mouse organs including the liver, heart, lung, spleen and kidney were harvested 4 d post-MNP-BV-CRISPR delivery and the genomic DNA was extracted for NGS analysis. Sitespecific gene modification was detected in the liver but not in the off-target organs (Fig. 6i ). As expected, without selecting baculoviral vector-transduced cells that are eGFP positive, the gene editing rates in the liver tissue samples collected somewhat randomly were much lower than with selection, since magnetic-field-activated baculoviral vector transduction was localized, and the liver samples for NGS were chosen by guessing where the magnetic field was effectively applied. Nevertheless, the NGS results shown in Fig. 6i confirm that there was efficient magnetic-field-driven genome editing with high tissue specificity. To determine whether spatial control of genome editing can be realized in another tissue, we also performed genome editing in the tumour-carrying mice following systemic injection of MNP-BV-CRISPR. The tumour was placed between two block magnets for 1 h following injection, and the analysis of gene editing in the tumour was performed in eGFP-positive cells selected using the workflow illustrated in Fig. 5e . Gene modifications at the Vegfr2 locus in the transduced cells in the tumour were quantified by both T7E1 assay and NGS analysis. Indels due to specific gene editing were detected in the tumour, albeit at a lower frequency compared with those induced by intratumoral injection ( Supplementary Fig. 21 ). The decrease in the gene editing efficiency was probably due to the limited amount of MNP-BV penetrating into the tumour stroma 47 .
Taken together, our results provide strong evidence of efficient magnetic-field-driven baculoviral vector transduction and transgene expression in different organs, and of spatially controlled genome editing in different tissues, such as the liver and tumour. Specifically, our in vivo studies demonstrate that the nuclease activity of the CRISPR-Cas9 system packaged in MNP-BV can be induced in the target tissues/organ on demand by the applied magnetic field, and both direct and systemic injection of MNP-BV enable site-specific genome editing. The MNP-BV-based in vivo delivery system takes advantage of the ability of nanomagnets to overcome baculoviral vector inactivation locally, thus enabling spatial control of in vivo gene delivery and genome editing. Our studies also provide insight into the mechanism of binding between baculoviral vector and TATmodified magnetic nanoparticles, and how the MNP-BV system prevents complement inactivation of baculoviral vector. Effective transduction of the MNP-BV complex in vivo is 'triggered' by the applied magnetic field, which serves as an activator of transgene expression and genome editing. Baculoviral vector activation and gene editing efficiency depend on the strength and spatial distribution of the magnetic field, distribution of MNP-BV in the tissue and accessibility of the target gene in somatic cells. In this proof-of-concept study, although the block magnets used for both in vitro and in vivo experiments could generate a strong magnetic field (1.48 Tesla), the resulting magnetic force applied to the MNPs attached to baculoviral vector varied with the location (distance and angle relative to the block magnet) of the MNP-BV complex. Due to the size of the magnet used (see Supplementary Fig. 19 ) and the challenge in positioning the block magnet very close to the mouse spleen, under systemic delivery, it was difficult to have baculoviral vector transduction only in the spleen, and not in the liver (which is next to the spleen and has a much larger size). Furthermore, when delivered systemically, it is likely that MNP-BVs could only be transduced in the vascular endothelium in the tumour and the few layers of stroma cells behind the leak vessel, resulting in a much-reduced gene editing rate compared with local injection. With a large magnetic device consisting of a set of coils optimally positioned, a strong magnetic field gradient could be applied anywhere in the body, thus overcoming these limitations. Efficient gene editing in specific cells in the target tissue can be achieved by optimizing the route of administration. Owing to the large DNA loading capacity of baculoviral vector, the MNP-BV-based delivery system also has the potential to facilitate multiplexed genome editing in vivo.
Methods
Production of baculoviral vector. Recombinant baculoviral vectors, including BV-LUC, BV-eGFP and BV-CRISPR, were constructed using the Bac-to-Bac baculovirus expression system (Thermo Fisher Scientific). Briefly, the expression cassette of cytomegalovirus (CMV)-luciferase, elongation factor 1α (EF1α )-eGFP or EF1α -eGFP-U6-sgRNA-CBh-Cas9 (where U6 is Pol III promoter, sgRNA is single guide RNA, and CBh is chicken β actin hybrid promoter) was inserted into the pFastBac vector and transformed into DH10Bac competent cells. The recombinant bacmids containing virus genome and the expression cassette were extracted using the PureLink HiPure Plasmid Miniprep Kit (Thermo Fisher Scientific). The recombinant bacmids were transduced into Spodoptera frugiperda insect cells using Cellfectin II (Thermo Fisher Scientific). The insect cell culture medium containing the budded viruses was centrifuged and filtered to remove cell debris using Bottle Top Filters (0.45 μ m; Thermo Fisher Scientific). The collected recombinant baculoviral vector was amplified in S. frugiperda insect cells for two more passages. Passage 3 was used for in vitro and in vivo studies. To concentrate and purify the viral particles, baculoviral vector was centrifuged at 18,600g (JLA-10.500 rotor, Beckman Coulter) for 150 min at 4 °C. The virus pellets were dispersed with 1 ml of PBS. Collected baculoviral vector was centrifuged on a sucrose cushion (25% sucrose with 5 mM NaCl and 10 mM EDTA) at 80,000g (55.2 Ti rotor, Beckman Coulter) for 75 min at 4 °C. The virus pellets were dispersed with 0.5 ml of PBS and stored at 4 °C. The titre of baculoviral vector stocks was determined using both the plaque assay and the qPCR titration assay ( Supplementary Fig. 1 ).
Synthesis of MNPs.
MNPs were synthesized according to previously published protocols 37, 38 . In brief, magnetite nanocrystals were synthesized through thermodecomposition of Fe(acac) 3 (Sigma-Aldrich) in benzyl ether using oleic acid (Sigma-Aldrich) and oleylamine (Sigma-Aldrich) as the capping molecules 37 . As-synthesized nanocrystals were coated with DSPE-mPEG2000 (Avanti Polar Lipids) and DSPE-PEG-maleimide (Avanti Polar Lipids) at a molar ratio of 9:1 using a dual solvent exchange method 38 . To conjugate peptides to the surface of MNPs, freshly coated MNPs were mixed with cys-TAT peptides (CGYGRKKRRQRRR; GenScript) or (Arg) 12 -cys (RRRRRRRRRRRRC; GenScript) at a molar ratio of 1:400 in PBS and incubated overnight. Unconjugated peptides were removed by washing the nanoparticles with deionized water in centrifugal filter tubes (cut-off molecular weight = 100 kDa). The physical properties of the MNPs were characterized using TEM, dynamic light scattering (Möbius, Wyatt Technology) and a superconducting quantum interference device (MPMS; Quantum Design).
In vitro magnetic pulldown study. BV-LUC (2 × 10 8 plaque-forming units (p.f.u.)) or AdV-LUC (with adenovirus instead of baculoviral vector; 2 × 10 8 p.f.u.; Vector Biolabs) were mixed with 20 µ g iron of unconjugated MNPs (MNP-PEG), MNPs conjugated with TAT (MNP-TAT) or MNPs conjugated with (Arg) 12 (MNP-polyArg) in PBS for 20 min. In the heparin group, MNP-TAT was first mixed with heparin (10 units) for 20 min before mixing with baculoviral vector. Then, the mixtures were added to 500 µ l culture medium in 8-well chamber slides. In the serum group, the medium contained 50% AMS. The chamber slides were incubated on a magnetic plate for 10 min with gentle shaking. Finally, 50 µ l supernatant was collected and copies of free viruses were quantified by qPCR (BacPAK qPCR Titration Kit; Clontech).
Cell culture. Hepa 1-6 cells, human cervical adenocarcinoma cells (HeLa) and human glioblastoma cells (U87) were purchased from the American Type Culture Collection. HUVECs were purchased from Lonza. All cells were cultured according to the standard protocols provided by the distributors, without further authentication. The cells were tested for Mycoplasma routinely.
In vitro baculoviral vector transduction. In vitro baculoviral vector transduction was performed with either BV-eGFP, BV-LUC or BV-CRISPR. eGFP fluorescence was used to evaluate the transduction efficiency or spatial distribution of baculoviral vector transduction. Luciferase activity was used to examine the level of transgene expression. In a typical in vitro baculoviral vector transduction experiment, the cells were seeded in a chamber slide. Before baculoviral vector transduction, 2 × 10 6 p.f.u. baculoviral vector was mixed with 4 µ g iron of MNPs for 20 min. Then, the cells were incubated with the mixture for 30 min with or without the magnet. In each group, the cells were transduced with baculoviral vector at an MOI of 100 p.f.u. per cell unless otherwise specified. After transduction, the cells were incubated with fresh medium. At 24 h post-transduction, the cells transduced by BV-eGFP were examined for eGFP fluorescence by flow cytometry or fluorescence microscopy. For the cells transduced by BV-LUC, the luciferase activity was measured using an in vitro luciferase kit (ONE-Glo Luciferase Assay System; Promega) in a microplate reader. The cells transduced with BV-CRISPR were cultured for 72 h and the genomic DNA was extracted and analysed by T7E1 assay for gene editing efficiency, as described below.
Cytotoxicity study. Hepa 1-6 cells were cultured in 96-well plates and incubated with baculoviral vector at designated MOIs with or without MNPs for 12 h. After treatment, the cells were incubated in fresh medium for 3 d and cell viability was evaluated by MTT assay.
Immunofluorescence staining. The cells were seeded in chamber slides and incubated with baculoviral vector or MNP-BV under designated conditions. After treatment, the cells were fixed in 4% paraformaldehyde for 20 min, permeabilized with PBS containing 0.1% Triton for 3 min and blocked with 5% bovine serum albumin for 1 h at room temperature. Baculoviral vector was detected by incubating the cells with an antibody against vp39 (kindly provided by L. Volkman and T. Ohkawa) overnight at 4 °C followed by an Alexa Fluor 647 goat antimouse IgG antibody (Abcam) 48 . Then, the cells were stained with Alexa Fluor 488 phalloidin (Thermo Fisher Scientific) and Hoechst 33342 (Thermo Fisher Scientific). Images were acquired with a confocal microscope (Nikon A1 Confocal Microscope). 
Genomic

Magnetically activated baculoviral vector transduction in vivo.
All animal studies were approved by the Institutional Animal Care and Use Committee at Rice University. Athymic nude mice (4-5-week-old females) were purchased from Charles River Laboratories. C3 knockout mice were purchased from the Jackson Laboratory. The mice were randomly allocated to the experimental groups without blinding. In the mouse tumour model, 3 × At 24 h post-injection, each mouse was injected with in vivo luciferase substrate (Promega) intraperitoneally and imaged using an IVIS Kinetic III live imaging system (PerkinElmer). Then, the mice were immediately euthanized and the tumour and vital organs were dissected for ex vivo imaging.
To investigate MNP-BV-induced transduction via systemic injection, the mice were injected with BV-LUC (10 9 p.f.u.) or MNP-BV-LUC (10 9 p.f.u. baculoviral vector mixed with 0.1 mg of iron MNP) dispersed in 200 µ l sterile PBS through the tail vein. To activate baculoviral vector transduction in the liver, the mice were placed on a grade N52 NdFeB block magnet (L × W × H = 1″ × 1/2″ × 1/2″ ) for one hour under anaesthesia ( Fig. 6a ). At 24 h post-transduction, each mouse was injected with in vivo luciferase substrate (Promega) intraperitoneally and the luciferase activity was examined using the IVIS imaging system. Then, the mice were euthanized immediately and vital organs were dissected and imaged ex vivo.
Magnetically activated in vivo genome editing. Tumour-bearing mice were used to test genome editing in tumours via direct injection. The mice were injected with MNP-BV-CRISPR as described above. One group of mice was euthanized on day 1 post-injection. Tumours were harvested, minced under sterile conditions and digested in Hank's Balanced Salt Solution containing 300 U ml −1 collagenase (Stem Cell Technology), 100 U ml −1 hyaluronidase (Stem Cell Technology) and 1 mg ml −1 DNase I (Stem Cell Technology) for 1 h at 37 °C with periodic shaking. Undigested tissue fragments were further treated with 0.25% Trypsin-EDTA (Gibco) for 5 to 10 min. The isolated cells were collected through a cell sieve (100 μ m; Greiner Bio-One). The red blood cells were removed with the red blood cell lysing buffer (Sigma-Aldrich). The remaining cells were sorted for GFP using a BD FACSMelody Cell Sorter. The cutting efficiency of the target gene was examined in sorted cells by T7E1 assay. The induced indel patterns were evaluated by NGS. Another group of mice was euthanized on day 4 and the gene editing frequencies in the tumour and vital organs were evaluated by NGS in the gene segments amplified directly from tissue homogenate.
To test genome editing via systemic injection, the mice were injected with MNP-BV-CRISPR and subjected to the magnetic treatment. Editing of the target gene was examined as described above. In the group for the T7E1 assay, the liver was harvested and the liver cells were isolated using a Liver Dissociation Kit (Miltenyi Biotec).
In vivo toxicity of MNP-BV. To examine the in vivo toxicity of MNP-BV, vital organs and blood were harvested from treated mice after 10 d post-injection. The organs were fixed in 10% formalin solution overnight and embedded in paraffin. Histology evaluation was performed in tissue sections stained with haematoxylin and eosin. Alanine transaminase and aspartate aminotransferase levels in the blood were measured using the ALT ELISA Kit (Biocompare. com) and AST Colorimetric Kit (BioVision), respectively, according to the manufacturers' instructions.
Statistics. GraphPad Prism (GraphPad Software) was used for all the calculations. Data were analysed using one-tailed Student's t-tests, Mann-Whitney U-tests and one-way analysis of variance (ANOVA) with post-hoc Dunnett tests. A difference of P < 0.05 was considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant (P > 0.05)). A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Software and code
Policy information about availability of computer code
Data collection
Comsol Multiphysics and Matlab were used for the simulation of the magnetic field generated by the block magnets.
Data analysis
GraphPad Prism was used for statistical analysis. The custom script used to analyse the indels in the NGS data is available at https:// github.com/piyuranjan/NucleaseIndelActivityScript. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
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-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
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Sample size
No prior sample-size calculation was performed. In all studies, a sample size of 3-4 was used initially. Statistical analysis was performed on the collected data and the results were used to determine if more samples were needed.
Data exclusions Exclusion criteria were not used in this study.
Replication
All chemicals and cell lines were purchased from the vendors with sufficient quality controls. All plasmids used in this study were verified by appropriate sequencing. All experiments were recorded in a repeatable manner.
Randomization All cells and animals were randomized among groups.
Blinding
Blinding was not used in this study. The data analyses on luminescense intensity, genome editing efficiency, etc. were directly calculated with corresponding software, without decision making by the researchers.
Reporting for specific materials, systems and methods 
Antibodies
Antibodies used
The antibody against vp39 was a gift from Prof. Loy Volkman and Dr. Taro Ohkawa.
Validation
The antibody has been used in previous studies (refs. 41-43) .
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
Mouse hepatoma cells (Hepa 1-6), human cervical adenocarcinoma cells (HeLa), and human glioblastoma cells (U87) were purchased from ATCC. Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza.
Authentication
None of the cells were authenticated in the lab.
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Mycoplasma contamination
The cells were tested for mycoplasma routinely.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
Athymic nude mice (4-5 weeks old, female) were purchased from Charles River Laboratories. C3 knockout mice (4-5 weeks, female) were purchased from the Jackson Laboratory.
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
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Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
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Methodology
Sample preparation
All cells were cultured according to the standard protocols from the distributors. The cells were transduced with adenovirus, baculovirus, or the complex of magnetic nanoparticles and viral particles under designated conditions. For flowcytometry analysis, the cells were detached using trypsin-EDTA, washed with PBS and analyzed using BD Accuri C6 Plus.
Instrument
BD Accuri C6 Plus.
Software
FlowJo.
Cell population abundance 10,000 events were collected in predetermined gates for each group.
Gating strategy
Gating was determined based on the distribution of the negative control (untransduced cells), which excluded 99.7% of the control cells ( Supplementary Fig. S4A ).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
